Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer

This study aimed to evaluate the effect of early dose reduction of osimertinib on efficacy and safety.  This was a retrospective study including patients withEGFR-mutated NSCLC who were started on osimertinib as the first-line therapy between August 2018 and December 2021. Patients whose doses were reduced to less than 80  mg/day within 6 months of osimertinib initiation or started at 40 mg/day were defined as the dose reduction group. The primary endpoint was progression-free survival (PFS). Factors affecting PFS were explored using the Cox proportional hazards model. A total of 85 patients were included in this study. No significant differences in patient characteristics were observed between the dose reduction (n = 25) and standard dose groups (n = 60). The median PFS in the dose reduction group was significantly prolonged compared with that in the standard dose group (26.0 months vs. 12.0 months,p = 0.03). Multivariable analysis of 84 patients, excluding a patient with unknown brain metastasis, revealed thatEGFR exon 21 L858R mutation, malignant pleural effusion or pleural metastasis, liver metastasis, and dose reduction within 6 months were independent factors affecting PFS.  Early dose reduction of osimertinib is an effective therapeutic strategy for prolonging PFS in patients withEGFR-mutated NSCLC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research